Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

Sponsor

Syneos Health (Other)

Overall Status

Recruiting

CT.gov ID

NCT05088369

Collaborator

Himuka AM Pharma Corp. (Other)

Enrollment

Location

Arms

12.6

Anticipated Duration (Months)

5.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This will be a single centre, Phase 1, Placebo-controlled, Randomized, Doubleblind, SAD & MAD Study to Assess the Safety, Tolerability and PK of HM201 in Healthy Subjects.

Condition or Disease	Intervention/Treatment	Phase
Ulcerative Colitis Crohn's Disease	Drug: HM201 Drug: Placebo Drug: HM201 Drug: Placebo	Early Phase 1

Detailed Description

Objective of the study is to assess the safety, tolerability, and PK of single and multiple intravenous administration of HM201. The study design consists of a SAD study of 4 cohorts, 8 subjects each cohort and a different dose level per cohort. In each cohort 2 will receive the placebo while rest of group will be administered with HM201. A total of 32 subjects are planned for the SAD study.

MAD part will begin after cohort 1 and 2 of SAD is completed. MAD will consist of 9 subjects; 2 will receive the placebo while 7 will be administered with HM201. MAD will be conducted in a dose escalation manner with 4 weekly doses administered to all subjects. One randomization scheme will be produced for each cohort separately.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

68 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

SAD & MAD studySAD & MAD study

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description:

This study will be conducted as a double-blind study. All subjects and clinical personnel will involved in the collection, monitoring, revision, safety and adverse events will be blinded in regards to the subject's treatment assigned of HM201 or the HM201 placebo. All personnel affecting the outcome of the study's treatment assignment will be blinded.

Primary Purpose:

Treatment

Official Title:

A First-in-human, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Intravenous Doses of HM201 (Pegylated Human Adrenomedullin) in Healthy Subjects (Adults)

Actual Study Start Date :

Nov 11, 2021

Anticipated Primary Completion Date :

Aug 1, 2022

Anticipated Study Completion Date :

Dec 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: SAD Cohorts 1 to 4: Participants receiving HM201 Each SAD cohort participant will be randomized to receive 1 of 4 escalating doses (0.01 mg/kg (2 nmol/kg); 0.03 mg/kg (5 nmol/kg); 0.06 mg/kg (10 nmol/kg); 0.12 mg/kg (20 nmol/kg).	Drug: HM201 HM201 will be administered intravenously. Other Names: Pegylated human adrenomedullin
Placebo Comparator: SAD Cohorts 1 to 4: Participants Receiving Placebo Each SAD cohort participant will be randomized to receive placebo.	Drug: Placebo Placebo will be administered intravenously. Other Names: Matching Placebo
Experimental: MAD Cohorts 1 to 4: Participants Receiving HM201 Each MAD cohort participant will be randomized to receive a once a week dose of 1 of 4 escalating doses (0.01 mg/kg (2 nmol/kg); 0.03 mg/kg (5 nmol/kg); 0.06 mg/kg (10 nmol/kg), 0.12 mg/kg (20 nmol/kg) for 4 weeks.	Drug: HM201 HM201 will be administered intravenously. Other Names: Pegylated human adrenomedullin
Placebo Comparator: MAD Cohorts 1 to 4: Participants Receiving Placebo Each MAD cohort participant will be randomized to receive placebo once a week for 4 weeks.	Drug: Placebo Placebo will be administered intravenously. Other Names: Matching Placebo

Outcome Measures

Primary Outcome Measures

Number and percentage of treatment-emergent adverse event, serious adverse event and discontinuation. [Up to 15 days post last infusion for both SAD & MAD]

Secondary Outcome Measures

Plasma concentrations of HM201 [SAD: Up to Day 15. MAD: Up to Day 36]
Pharmacokinetic assessment 1 [SAD: Up to Day 15. MAD: Up to Day 36]
Area under the plasma concentration versus time curve (AUC)
Pharmacokinetic assessment 2 [SAD: Up to Day 15. MAD: Up to Day 36]
Peak Plasma Concentration (Cmax)
Pharmacokinetic assessment 3 [SAD: Up to Day 15. MAD: Up to Day 36]
Time of peak plasma concentration (Tmax)
Pharmacokinetic assessment 4 [MAD: Up to Day 36]
Concentration at the last planned timepoint prior to dosing (Ctrough)
Pharmacokinetic assessment 5 [SAD: Up to Day 15. MAD: Up to Day 36]
Mean residence time (MRT)
Pharmacokinetic assessment 6 [SAD: Up to Day 15. MAD: Up to Day 36]
Drug clearance (CL) & Clearance at steady state (CLss)
Pharmacokinetic assessment 7 [SAD: Up to Day 15. MAD: Up to Day 36]
Volume of distribution at steady state (Vss) & during terminal phase (VZ)
Pharmacokinetic assessment 8 [SAD: Up to Day 15. MAD: Up to Day 36]
Half life (T1/2)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Key Inclusion Criteria:

Healthy male or non-childbearing potential female
BMI ≥18.0 and ≤32.0 kg/m2
Good health based on past medical history, medication use, vital signs and physical exam.
Normal renal and hepatic function.
Female partners of child bearing potential must agree to use contraception.

Key Exclusion Criteria:

Clinically significant medical history.
Significant drug allergy.
Use of experimental drug within 3 months prior.
Previously received HM201, AM and other derivatives.
History of old myocardial infarction.
Diagnosed with malignant tumor or history of treatment for malignant tumor.
History of drug or alcohol abuse.
Use of omitted medicines or substance opposing objective of study.
COVID19 vaccine administered within 14 days of initiation of investigational product or if to receive additional dose within 30 days of investigational product administration.
Use of tobacco/nicotine in excess of ≥ 5 cigarettes a day and unable or unwilling to prohibit smoking during admission to site.
Daily consumption of more than 1L of caffeine/xanthine beverage which cannot be discontinued more than 24 hours prior to dosing of investigational product and/or ECG measurement.
Regular use of nutraceuticals (e.g., St. John's wort, ginseng, ginkgo biloba, Chinese herbs, and melatonin) within 1 week before administration of investigational product.
Donation of plasma or platelet or 200 mL of whole blood within 4 weeks or 400 mL whole blood within 3 months before administration of investigational product.
Clinically relevant findings in ECG.
Systolic blood pressure below 100 mmHg or above 140 mmHg at screening.
Diastolic blood pressure above 90 mmHg at screening.
Heart rate below 40 beats/min or above 100 beats/min at screening.
Symptom of orthostatic hypotension is found at screening or before investigational product administration (Day -1).
Hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antibody (HBcAb) hepatitis C virus antibodies (anti-HCV) or human immunodeficiency virus (HIV) antigen and antibody at screening.
Positive to syphilis.
Positive to urine drug test.
Positive alcohol breath test.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Nucleus Network Pty Ltd	Herston	Queensland	Australia	4006

Sponsors and Collaborators

Syneos Health
Himuka AM Pharma Corp.

Investigators

Principal Investigator: Kristi McLendon, MD, Nucleus Network Pty Ltd

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Syneos Health

ClinicalTrials.gov Identifier:

NCT05088369

Other Study ID Numbers:

HM201-AUS-001

First Posted:

Oct 21, 2021

Last Update Posted:

Apr 27, 2022

Last Verified:

Apr 1, 2022

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Crohn Disease

Adrenomedullin

Study Results

No Results Posted as of Apr 27, 2022